0.709

1.29% 0.009

After Hours: .68 -0.029 -4.09%

Evogene Ltd (EVGN)

Overview News Price History Option Chain Discussions Forecast Stock Split

Evogene Ltd stock is traded at $0.709, with a volume of 76,876. It is up +1.29% in the last 24 hours and down -10.03% over the past month. Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules, and genetic elements as the core components for such products. It holds several subsidiaries utilizing the CPB platform for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits, and ag-solutions for castor oil production. It generates maximum revenue from the industrial segment, followed by Agriculture.

Previous Close:

$0.70

Open:

$0.73

24h Volume:

76,876

Relative Volume:

0.78

Market Cap:

$7.38M

Revenue:

$3.95M

Net Income/Loss:

$-14.59M

P/E Ratio:

-0.6098

EPS:

-1.1626

Net Cash Flow:

$-14.46M

1W Performance:

-4.70%

1M Performance:

-10.03%

6M Performance:

-37.53%

1Y Performance:

-39.40%

1-Day Range:

$0.68

$0.7361

1-Week Range:

$0.66

$0.7654

52-Week Range:

$0.66

$2.42

Evogene Ltd Stock (EVGN) Company Profile

Name

Evogene Ltd

Sector

Healthcare (1111)

Industry

Biotechnology (621)

Phone

Address

Employee

Twitter

@evogene_ltd

Next Earnings Date

2026-05-20

Latest SEC Filings

EVGN's Discussions on Twitter

Compare EVGN vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
EVGN Evogene Ltd	0.709	7.29M	3.95M	-14.59M	-14.46M	-1.1626
VRTX Vertex Pharmaceuticals Inc	435.93	110.28B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	634.62	66.98B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	808.43	50.15B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	295.50	39.71B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	154.89	32.22B	742.00K	-1.37B	-1.07B	-7.0731

Evogene Ltd Stock (EVGN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-08-21	Initiated	ROTH Capital	Buy
Jul-29-21	Initiated	Aegis Capital	Buy
Dec-01-20	Initiated	Cantor Fitzgerald	Overweight
Dec-16-13	Initiated	Oppenheimer	Outperform

Evogene Ltd Stock (EVGN) Latest News

May 23, 2026

Evogene shares decline after revenue miss despite stronger-than-expected earnings (EVGN) - MSN

May 23, 2026

May 22, 2026

Evogene Ltd (EVGN)

Evogene Ltd Stock (EVGN) Company Profile

Compare EVGN vs VRTX, REGN, ARGX, ALNY, RVMD

Evogene Ltd Stock (EVGN) Upgrades & Downgrades

Evogene Ltd Stock (EVGN) Latest News

Evogene shares decline after revenue miss despite stronger-than-expected earnings (EVGN) - MSN

Evogene Q1 2026 earnings preview - MSN

Evogene Ltd. (NASDAQ:EVGN) Q1 2026 Earnings Call Transcript - Insider Monkey

Evogene Reports First Quarter 2026 Financial Results - Dailyhunt

Evogene Ltd stock (IL0010831684): Q1 revenue slump highlights high?risk transformation phase - AD HOC NEWS

Evogene stock falls 5% on revenue miss despite earnings beat - Investing.com

Evogene Earnings Call: AI Momentum vs. Cash Strain - TipRanks

Evogene earnings beat by $0.26, revenue fell short of estimates - Investing.com Australia

Evogene Q1 2026 Loss Deepens: -$0.60/Share vs -$0.28 Expected - AlphaStreet

EVGN: Revenue fell sharply and net loss widened as focus shifted to core AI-driven pharma and ag chem - TradingView

Earnings call transcript: Evogene reports Q1 2026 loss, stock rises 1.95% - Investing.com Australia

EVGN: AI-driven pharma and ag chemical focus advances, but Q1 revenue drops and net loss widens - TradingView

Evogene Ltd. Q1 2026 Earnings Call Summary - Yahoo Finance

Evogene Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com

Evogene reports Q1 results: net loss widens amid revenue decline - grafa.com

Evogene Shares Decline After Revenue Miss Despite Stronger-Than-Expected Earnings (EVGN) - Yahoo Finance

Evogene Ltd reports results for the quarter ended March 31Earnings Summary - TradingView

Evogene Ltd files for offering of 2.45 million ordinary shares by selling shareholder SEC filing - marketscreener.com

Evogene 1Q Loss/Shr 60c >EVGN.TV - Moomoo

Evogene Ltd Files For Offering Of 2.45 Million Ordinary Shares By Selling Shareholder SEC Filing - TradingView

Evogene (NASDAQ: EVGN) registers 2.45M shares for resale, files Q1 2026 results - Stock Titan

Evogene Tightens Focus on AI Small-Molecule Platform as Q1 2026 Revenue Falls - TipRanks

Evogene : Q1 2026 Consolidated Financial Statements - marketscreener.com

EVOGENE ($EVGN) Releases Q1 2026 Earnings - Quiver Quantitative

Evogene stock falls 5% on revenue miss despite earnings beat By Investing.com - Investing.com Australia

EVGN: Q1 2026 revenue declined and net loss widened, but AI-driven pipeline and partnerships advanced - TradingView

Evogene: Q1 Earnings Snapshot - marketscreener.com

Evogene (EVGN) Q1 2026 shows sharp revenue fall, wider loss and cash burn - Stock Titan

Press Release: Evogene Reports First Quarter 2026 Financial Results - Moomoo

Evogene Q1 2026 Earnings Call Transcript - MarketBeat

EVGN Q1'26 Earnings: EPS estimate is (0.27) USD - TradingView

Evogene’s Ag Plenus, Bayer End Herbicide Collaboration as APTH1 Target Falls Short - TipRanks

Evogene (EVGN) and Bayer terminate herbicide project, APTH1 assets return to AgPlenus - Stock Titan

Evogene Ltd expected to post a loss of 27 cents a shareEarnings Preview - TradingView

Evogene Ltd stock (IL0010831684): AI-driven biotech draws attention after recent financing update - AD HOC NEWS

Evogene Ltd.Ordinary Shares (NQ: EVGN - The Chronicle-Journal

Armistice Capital and Steven Boyd report 9.99% of EVGN (May 2026) - Stock Titan

Earnings Preview: Evogene to Report Financial Results Pre-market on May 20 - Moomoo

Evogene (EVGN) Institutional Ownership 2026 - MarketBeat

Evogene Ltd stock (IL0010831684): recent financing move and pipeline focus draw investor attention - AD HOC NEWS

AI-designed drug molecules: Evogene presents GenAI model in Munich - Stock Titan

Evogene to Present at the 24th Schrödinger European User Group Meeting - marketscreener.com

TradingKey - TradingKey

Evogene will discuss first-quarter results on a May 20 Zoom call - Stock Titan

Evogene Schedules First Quarter 2026 Financial Results Release - Barchart.com

Genetically Modified Seeds Market 2026 Growth, Industry - openPR.com

Evogene receives Nasdaq notification - MSN

Evogene files for resale of 5.08M shares via warrant exercise - MSN

Evogene Ltd Stock (EVGN) Financials Data

Revenue

Net Income

Cash Flow

EPS

Similar to EVGN